169205-78-1 | N4-(3-Bromophenyl)quinazoline-4,6-diamine

Packsize	Purity	Availability	Price	Discounted Price
25mg	95%	in stock	$53.00	$37.00
250mg	95%	in stock	$90.00	$63.00
1g	95%	in stock	$246.00	$172.00
5g	95%	in stock	$1,089.00	$762.00

Description

• Catalog Number: AA91247
• Chemical Name: N4-(3-Bromophenyl)quinazoline-4,6-diamine
• CAS Number: 169205-78-1
• Molecular Formula: C14H11BrN4
• Molecular Weight: 315.1679
• MDL Number: MFCD09908082
• SMILES: Brc1cccc(c1)Nc1ncnc2c1cc(N)cc2

Computed Properties

• Complexity: 301
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: 3.4

Literature

• Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.

  Journal of medicinal chemistry 20120308

• Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.

  European journal of medicinal chemistry 20120301

• The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.

  Bioorganic & medicinal chemistry 20110815

• The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.

  The Journal of pharmacology and experimental therapeutics 20100701

• Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.

  Journal of medicinal chemistry 20100311

• N-(3-Bromo-phen-yl)quinazoline-4,6-diamine.

  Acta crystallographica. Section E, Structure reports online 20100201

• Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging.

  European journal of medicinal chemistry 20091001

• Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.

  Nature chemical biology 20070401

• The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).

  Journal of medicinal chemistry 20060615

• Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.

  Journal of medicinal chemistry 20031204

• The combi-targeting concept: chemical dissection of the dual targeting properties of a series of 'combi-triazenes'.

  Journal of medicinal chemistry 20030925

• 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

  Journal of medicinal chemistry 20010816

• Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.

  Journal of medicinal chemistry 19970606

• Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

  Journal of medicinal chemistry 19960105